未找到相关数据
Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study
被引：0
作者：
Naing, Aung
Mamdani, Hirva
Barve, Minal A.
Johnson, Melissa Lynne
Morgensztern, Daniel
Olszanski, Anthony J.
Wolff, Robert A.
Pant, Shubham
Chaney, Marya F.
Adebanjo, Tolani
Fan, Jean
Kim, Richard D.
Kopetz, Scott
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[2] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[3] Texas Oncol, Dallas, TX USA
[4] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Fox Chase Canc Ctr, Philadelphia, PA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[8] Merck & Co Inc, Kenilworth, NJ USA
[9] NeoImmuneTech Inc, Rockville, MD USA
[10] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2514
引用
收藏
页数：1
相关论文